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| INTRODUCTION
Peptide-based cancer vaccines are considered a promising therapeutic strategy; however, their clinical results have been unsatisfactory for the past 2 decades. [1] [2] [3] One reason for this is the difficulty in selecting efficient TAA because of the heterogeneity of tumor cells and the diversity of immune responses. After much consideration, PPV was developed in which individual patients are vaccinated with multiple peptides based on HLA type and pre-existing immunity by measuring peptide-specific IgG levels.
The clinical benefits of PPV for several advanced urological cancers, including CRPC and advanced UC, have been reported in clinical trials. [4] [5] [6] However, there are several concerns to be addressed to develop more efficacious PPV treatment for precision immunotherapy. One is how to determine more clinically effective peptides from IgG-positive peptide candidates prior to PPV treatment. Although all candidate peptides provided for PPV treatment had equal capability to induce CTL activity in vitro in PBMC, and pre-existing IgG responses to these peptides were equally detectable in cancer patients, 3, 7, 8 equal capability of each peptide at the clinical level is not guaranteed, and there are no methods available to discriminate clinically efficacious peptides among the candidates prior to PPV treatment.
We aimed to evaluate the selection of clinically correlated peptides based on OS according to HLA types in 154 patients with CRPC and in 111 patients with advanced UC treated by PPV.
| PATIENTS AND METHODS

| Candidate peptides
In PPV treatment, 31 candidate peptides from 15 TAA were prepared under the conditions of Good Manufacturing Practice using a Multiple Peptide System (San Diego, CA, USA). All 31 candidate peptides were CTL epitopes restricted to the HLA-A2, -A24 or -A3 families (HLA-A3, -A11, -A31 or -A33) of MHC class I molecules, which covered the majority of the general population. Names of peptides, coding TAA, amino acid sequences, and HLA types are given in Table 1 . Expression levels of the 15 TAA that code the peptides used for PPV treatment were examined by IHC of primary prostate cancer tissues (n = 10), metastatic lymph nodes from prostate cancer (n = 4), and primary UC tissues (n = 10) obtained from nonvaccinated patients. Detailed methods, including antibodies used for staining, were previously described. 
| Immune responses to individual peptides
Individual peptide-specific IgG and CTL responses were analyzed in blood samples before and after the first cycle of PPV treatment. IgG responses were measured by the Luminex system (Luminex, Austin, TX, USA) using plasma, and the CTL responses were evaluated by IFN-γ ELISPOT assay (MBL, Nagoya, Japan) using PBMC as previously described. 22, 23 Higher IgG titers to vaccinated peptides at the end of the first cycle than those in prevaccination plasma and more than 30 spots for the corresponding peptide in PBMC as observed by IFN-γ ELISPOT assay were considered to be positive immune responses.
| Statistics
Baseline characteristics, vaccinated peptides, immunological responses to vaccinated peptides, OS during PPV treatment, and follow up were extracted from the database of the 5 clinical PPV trials.
Student's t test and the chi-squared test were used to compare quantitative and categorical variables, respectively. OS was calculated as the time in months from the date of study enrollment to death or to the date of last contact. Time-to-event endpoints were analyzed using the Kaplan-Meier method, and between-group comparisons for OS were conducted using the log-rank test. 3 | RESULTS
| Expression of tumor antigens
In the 10 primary prostate cancer tissues tested, 4 TAA (PSA, PSMA, PTHrP, and CypB) were highly expressed in the majority 
| Baseline characteristics
| Estimation of correlated peptides
Peptides used in <10% of all patients were excluded from the univariate Cox regression analysis to avoid bias as follows:
Lck208, MRP3-503, and EZH2-735 for HLA-A24, Lck-422, and UBE2V-85 for HLA-A2, and Lck-422 for the HLA-A3 family in CRPC patients (Table 3) ; MRP3-503, SART2-161, and EZH2-735
for HLA-A24, Lck-422, and UBE2V-85 for HLA-A2, and Lck-422
for the HLA-A3 family in advanced UC patients ( CI 0.03-0.67; P = .01) for HLA-A2, and SART3-734 for the HLA-A3 family were also considered to be correlated peptides (Table 4 ). All correlated peptides showed peptide-specific IgG and CTL responses at the end of the first cycle of PPV treatment (Table 5 ).
| Effectiveness of peptides correlated with OS
We also carried out an OS subgroup analysis based on groups stratified by use of correlated peptides according to HLA type ( Figure 2 ).
In CRPC, median OS times for patients with correlated peptides were significantly longer than for those without correlated peptides: 
| DISCUSSION
In the present study, we indicated using 265 advanced urological cancer patients treated by PPV that correlated peptides selected by both Importantly, analyzed survival data were obtained from a cohort of urological cancer patients who had equally poor prognostic backgrounds.
Most peptides previously used in cancer vaccines in clinical trials
were able to induce peptide-specific IgG or CTL responses but had no clinical benefits. This may be due to many factors, including the poor immunogenicity of TAA, inadequate peptide selection and tumor heterogeneity. 24 In addition, the limited clinical efficacy may be a result of not knowing the immunological status of patients, which leads to mismatches between used peptides and heterogeneous immune cell repertoires. respectively. 25 Combination therapy with cancer vaccination and anti-PD-1 antibody in murine cancer models enhanced TIL antigen reactivity and prolonged the survival of tumor-bearing mice. 26, 27 We therefore expect combination therapy with peptide-based vaccination and immune checkpoint blockade to be an effective strategy for peptidebased vaccine failure or immune checkpoint blockade failure.
Unlike other peptide-based vaccines, PPV is a novel immunotherapy approach for cancer patients. In PPV treatment, many suitable candidate peptides are selected based on HLA type and the pre-existing host immunity. Conventional peptide-based vaccines containing only 1 peptide may not initiate a specific antitumor response in tumor cell variants because of the loss or reduction in TAA. 28 In this study, we found that the majority of TAA coding candidate peptides used in PPV treatment were expressed in tumor cells from prostate cancer or UC samples, except for p56Lck in both, and PSA, PAP and PSMA in the UC samples. However, p56Lck was expressed in TIL from all 
